CompletedNot Applicable

Prognostic Value of miR-21 and miR-486 in Pulmonary Nodule Surgery

China138 participantsStarted 2020-01-01

Plain-language summary

This study prospectively evaluated the prognostic value of microRNA-21 (miR-21) and microRNA-486 (miR-486) expression in patients with pulmonary nodules who underwent clock-guided minimally invasive surgery. The study aimed to determine if high expression levels of these miRNAs in resected nodule tissue correlate with poorer clinical outcomes, including larger residual tumor size, higher metabolic activity, and shorter overall and progression-free survival.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years; * Single or multiple pulmonary nodules confirmed by imaging; * Pathologically confirmed or highly suspected malignancy; * Eligible for clock-guided minimally invasive surgery; * No contraindications to surgery; * Signed informed consent. Exclusion Criteria: * Uncontrolled comorbidities (e.g., hypertension \>180/110 mmHg, HbA1c \>9%); * Inoperable status; * Benign nodules confirmed by pathology; * Severe organ dysfunction (e.g., LVEF \<40%, eGFR \<30 mL/min); * Immunosuppressive therapy; * Recent anticancer treatment (\<3 months); * Lost to follow-up.

What they're measuring

Overall Survival (OS)

Timeframe: Assessed up to January 2022 (up to 24 months of follow-up)

Progression-Free Survival (PFS)

Timeframe: Assessed up to January 2022 (up to 24 months of follow-up)

Trial details

NCT IDNCT07060287

SponsorThe First Hospital of Hebei Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-01-01

View on ClinicalTrials.gov More Pulmonary Nodule Cm trials